Literature DB >> 21904653

Positron emission tomography neuroimaging in Parkinson's disease.

Clare Loane1, Marios Politis.   

Abstract

Positron emission tomography (PET) is a nuclear imaging technique, which allows in vivo estimations of important physiological parameters such as, glucose metabolism and neuroreceptor binding enabling greater understanding of the pathophysiology of Parkinson's disease (PD). The review will evaluate the role of PET in assessing both the dopaminergic (DA) and non-DA systems in relation to the pathophysiology of PD, differential diagnosis, progression of disease and pre-clinical disease. Medication side effects, genetic forms of PD, the non-motor symptoms of PD and alternative restorative approaches will also be discussed in relation to how PET imaging can enhance our understanding of these aspects of the disease. PET neuroimaging has to date, provided an excellent tool to assess the underlying mechanisms of the disease as well as evaluating the complications and management of PD and has the potential to be of great clinical value if the current limitations of costing and availability are resolved.

Entities:  

Keywords:  PET; Parkinson's disease; Positron Emission Tomography

Year:  2011        PMID: 21904653      PMCID: PMC3158735     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  126 in total

1.  Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways.

Authors:  R Hilker; A V Thomas; J C Klein; S Weisenbach; E Kalbe; L Burghaus; A H Jacobs; K Herholz; W D Heiss
Journal:  Neurology       Date:  2005-12-13       Impact factor: 9.910

2.  The comparative distribution of enkephalin, dynorphin and substance P in the human globus pallidus and basal forebrain.

Authors:  S N Haber; S J Watson
Journal:  Neuroscience       Date:  1985-04       Impact factor: 3.590

3.  An estimate of the worldwide prevalence and direct costs of dementia in 2003.

Authors:  A Wimo; L Jonsson; B Winblad
Journal:  Dement Geriatr Cogn Disord       Date:  2006-01-09       Impact factor: 2.959

4.  Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

Authors:  F J Vingerhoets; M Schulzer; D B Calne; B J Snow
Journal:  Ann Neurol       Date:  1997-01       Impact factor: 10.422

5.  Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.

Authors:  M Otsuka; Y Ichiya; Y Kuwabara; S Hosokawa; M Sasaki; T Yoshida; T Fukumura; K Masuda; M Kato
Journal:  J Neurol Sci       Date:  1996-03       Impact factor: 3.181

Review 6.  Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?

Authors:  Stephen J Kish
Journal:  Adv Neurol       Date:  2003

7.  A two-compartment description and kinetic procedure for measuring regional cerebral [11C]nomifensine uptake using positron emission tomography.

Authors:  E Salmon; D J Brooks; K L Leenders; D R Turton; S P Hume; J E Cremer; T Jones; R S Frackowiak
Journal:  J Cereb Blood Flow Metab       Date:  1990-05       Impact factor: 6.200

8.  Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging.

Authors:  M Ghaemi; R Hilker; J Rudolf; J Sobesky; W-D Heiss
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

9.  [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease.

Authors:  Ruediger Hilker; Noushin Razai; Mehran Ghaemi; Simon Weisenbach; Jobst Rudolf; Brigitte Szelies; Wolf-Dieter Heiss
Journal:  Clin Neurol Neurosurg       Date:  2003-09       Impact factor: 1.876

Review 10.  [Clinical utility of (18)F-DOPA-PET in movement disorders. A systematic review].

Authors:  J Puñal-Riobóo; A Serena-Puig; L Varela-Lema; A M Alvarez-Páez; A Ruano-Ravina
Journal:  Rev Esp Med Nucl       Date:  2009 May-Jun
View more
  24 in total

1.  Dual time point method for the quantification of irreversible tracer kinetics: A reference tissue approach applied to [18F]-FDOPA brain PET.

Authors:  I Lopes Alves; Sanne K Meles; Antoon Tm Willemsen; Rudi A Dierckx; Ana M Marques da Silva; Klaus L Leenders; Michel Koole
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-19       Impact factor: 6.200

Review 2.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

Review 3.  Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.

Authors:  Eugene M Cilento; Lorrain Jin; Tessandra Stewart; Min Shi; Lifu Sheng; Jing Zhang
Journal:  J Neurochem       Date:  2019-01-31       Impact factor: 5.372

Review 4.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

Review 5.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

6.  Human striatal recordings reveal abnormal discharge of projection neurons in Parkinson's disease.

Authors:  Arun Singh; Klaus Mewes; Robert E Gross; Mahlon R DeLong; José A Obeso; Stella M Papa
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-08       Impact factor: 11.205

Review 7.  The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review.

Authors:  Fernando Caravaggio; Shinichiro Nakajima; Eric Plitman; Philip Gerretsen; Jun Ku Chung; Yusuke Iwata; Ariel Graff-Guerrero
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-09-01       Impact factor: 5.067

8.  Joint feature-sample selection and robust diagnosis of Parkinson's disease from MRI data.

Authors:  Ehsan Adeli; Feng Shi; Le An; Chong-Yaw Wee; Guorong Wu; Tao Wang; Dinggang Shen
Journal:  Neuroimage       Date:  2016-06-10       Impact factor: 6.556

9.  Recent imaging advances in neurology.

Authors:  Lorenzo Rocchi; Flavia Niccolini; Marios Politis
Journal:  J Neurol       Date:  2015-03-26       Impact factor: 4.849

10.  A digital phoswich detector using time-over-threshold for depth of interaction in PET.

Authors:  David L Prout; Zheng Gu; Max Shustef; Arion F Chatziioannou
Journal:  Phys Med Biol       Date:  2020-12-15       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.